Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors.
Anil P BidkarDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1249-1081
Scott BidlingmaierDepartment of Anesthesia, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4955-9713
Anju WadhwaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0009-0006-0826-8134
Ellis MayneDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0009-0004-1917-2352
Athira RaveendranDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-4853-4330
Cheng XueDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0009-0004-2322-9980
Megha BasakDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2422-184X
Kondapa Naidu BobbaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-6304-2855
Bonell Patiño-EscobarDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-2622-4822
Nancy GreenlandDepartment of Pathology, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1783-1711
Juan Antonio Camara SerranoUCSF Helen Diller Family Comprehensive Cancer Center , San Francisco, California.ORCID 0000-0001-7494-1127
Veronica SteriUCSF Helen Diller Family Comprehensive Cancer Center , San Francisco, California.ORCID 0000-0003-2499-6618
Jonathan ChouDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1258-0391
Arun WiitaDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-7465-6964
Jiang HeDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia.ORCID 0000-0001-7600-4604
David M WilsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1095-046X
Rahul AggarwalDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-7003-7982
Henry F VanBrocklinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-2849-0841
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-5908-6636
Bin LiuDepartment of Anesthesia, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-9137-5067
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-8694-1199
Funding
Development of CD46 theranostics for imaging and treatment of multiple myelomaR01CA271606 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Robert Richard Flavell, Arun P. Wiita · 2022 to 2026
$3.3M
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancerR01CA223767 · NCI · UNIVERSITY OF VIRGINIA · PI HE, JIANG, LIU, BIN · 2018 to 2022
$2.8M
Targeting tumor-specific epitope for imaging and therapy for mesotheliomaR01CA288612 · NCI · UNIVERSITY OF VIRGINIA · PI Jiang He, BIN LIU · 2025 to 2026
$1.4M
High-throughput microPET/CT at UCSF Preclinical Imaging CoreS10OD034286 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEO, YOUNGHO · 2023 to 2023
$662k
Enhancing Prostate Cancer Treatment Outcomes with Combined Radioimmunotherapy and Antibody Drug ConjugatesK99CA304511 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Anil Parsram Bidkar · 2025 to 2026
$372k
DOD Prostate Cancer Research Program (PCRP) HT9425-23-1-0139DOD Prostate Cancer Research Program (PCRP) W81XWH-20-1-0136DOD Prostate Cancer Research Program (PCRP) W81XWH-20-1-0292DOD Prostate Cancer Research Program (PCRP) W81XWH-21-1-0792Foundation for the National Institutes of Health (FNIH) R01CA223767Foundation for the National Institutes of Health (FNIH) S10OD034286National Cancer Institute (NCI) K99CA304511National Cancer Institute (NCI) R01CA271606National Cancer Institute (NCI) R01CA279203National Institute of Biomedical Imaging and Bioengineering (NIBIB) R01EB026331NCI NIH HHS K99 CA304511NCI NIH HHS R01 CA223767NCI NIH HHS R01 CA271606NCI NIH HHS R01 CA288612Prostate Cancer Foundation (PCF)UCSF Benioff Institute for Prostate Cancer ResearchUCSF Cancer Imaging Resources and Preclinical Therapeutics Core P30CA082103UCSF Precision Imaging of Cancer and TherapyUCSF Prostate Cancer Research ProgramUCSF Resource Allocation Program
6 · The paper itself
Abstract
purposeCD46 is highly expressed across multiple cancer types, including prostate cancer and multiple myeloma. We have developed CD46-targeting antibody-drug conjugate (ADC) and actinium-225 (225Ac)-based α particle therapy agents that demonstrated a tumor-selective therapeutic effect. We hypothesized that a treatment strategy targeting CD46 using simultaneous ADC and radioimmunotherapy methods would have synergistic therapeutic efficacy with acceptable toxicity. EXPERIMENTAL
designTwo CD46-targeted combination treatment strategies were evaluated: (i) co-administration of the ADC (YS5-MMAE) and 225Ac-labeled antibody ([225Ac]Macropa-PEG4-YS5) and (ii) a dual-payload radioconjugate ([225Ac]Macropa-PEG4-YS5-MMAE; R-ADC). The in vitro synergy was studied using cell viability, DNA damage, and apoptosis assays. In vivo studies were performed for biodistribution, toxicity, and therapeutic evaluation in subcutaneous, disseminated, and patient-derived xenograft models of prostate cancer and multiple myeloma.
resultsCombination therapy induced synergistic G2-M arrest, increased γ-H2AX foci, and enhanced cell death compared with monotherapies. R-ADC and co-administration strategies resulted in improved tumor control and survival benefit.
conclusionsBy integrating orthogonal microtubule inhibition and high-linear energy transfer α irradiation on a single CD46 scaffold, potent, well-tolerated tumor control was achieved across diverse models. The dual-payload construct's compatibility with CD46 immuno-PET for real-time dosimetry further supports progression to early-phase clinical trials in prostate cancer and multiple myeloma.
Indexed as
ImmunoconjugatesMultiple MyelomaProstatic NeoplasmsRadioimmunotherapyActiniumAnimalsApoptosisCell Line, TumorHumansMaleMiceXenograft Model Antitumor AssaysActiniumActinium-225Immunoconjugates
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates. · full record | Socratic